Bowman Heiden participates in the webinar for a behind-the-scenes look at the joint LES/EPO special edition of les Nouvelles dedicated to high‐growth technology businesses that rely on IP for their success, on July 8th.
Our advisory board member, Paul Fehlner, has written an insightful article about IP and open innovation in Pharma.
It is important to note that designing the right amount of openness is often based on IP, not against IP. In the times of COVID19, the need for openness increases, but can easily be managed together with the IP system in combination with clever contractual solutions as this article explains.
You can read the article here